The Dopamine Radioreceptor Assay—A Clinical Application

Publisher Website
Google Scholar
Abstract
The counterbalanced design in a bioequivalent study of haloperidol [in man] indicated an absence of any clinical difference between a new 20 mg dosage form and two 10 mg tablets of haloperidol (Haldol). This impression was supported by the absence of any significant behavioral changes during the 4 wk when either form of the once-a-day fixed dose of 20 mg haloperidol was administered and by experiences with the dopamine receptor blocking assay, as results with this procedure indicated the lack of any significant difference in the plasma neuroleptic equivalence of either dosage form. The assay appears to offer promise for clinical application in the adjusting of the dosage of neuroleptic drugs and in the monitoring of drug usage.